A robust and stable reporter gene bioassay for anti-IgE antibodies
- 6 February 2020
- journal article
- research article
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 412 (8) , 1901-1914
Abstract
Immunoglobin E (IgE)-related allergy constitutes a high proportion in allergic diseases. The production of specific IgE is key to evoking serial cascades and pathological reactions. Thus, targeting IgE is a different therapeutic approach from symptomatic treatments. Monoclonal antibodies (mAbs) against IgE were developed and a humanized antibody, omalizumab, was approved by five countries. It could inhibit the binding of IgE with epsilon receptor I of crystallizable fragment (FcεRI), thus preventing anaphylactic reactions. However, no bioactivity assay, which is the critical quality attribute and should thoroughly reflect the clinical mechanism, has been established to date. In commercial lot release, only the enzyme-linked immunosorbent assay (ELISA) method was applied, which only reflects the binding of omalizumab to IgE but not the subsequent reaction. In scientific research works, human FcεRI-transfected RBL-2H3 cells were used to indicate degranulation based on the detection of β-hexosaminidase. Nevertheless, this method needs much work to stabilize the response and, hence, is not suitable for routine usage in commercial production and control of antibodies. To evaluate the bioactivity of anti-IgE antibodies including omalizumab using a simple assay that reflects the following mechanism of actions (MOA) after binding, we established an RBL-2H3 cell line transfected with both the α subunit of human FcεRI and nuclear factor-activated T cell (NFAT) response elements, the latter is conjugated with a luciferase gene, which could shed luminescence when substrates exist. The method was proven to possess good specificity, accuracy, linearity, and precision and may be utilized as a supplement to anti-IgE antibody bioactivity assays in terms of development, lot release, stability, and comparability studies. The mechanism sketch of reporter gene assay for bioactivity determination of anti-IgE antibodies by RBL-2H3/FcεRIα/NFAT-Luc cells (left) and representative curves generated by the reporter gene assay (right).Keywords
Funding Information
- National Science and Technology Major Projects for major new drugs innovation and development (2018ZX09736-008)
This publication has 43 references indexed in Scilit:
- Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparationsEuropean Journal of Pharmacology, 2013
- Histamine release and surface CD200R1 staining as sensitive methods for assessing murine mast cell activationJournal of Immunological Methods, 2012
- A convenient and sensitive allergy test: IgE crosslinking‐induced luciferase expression in cultured mast cellsAllergy, 2010
- After 6 years with Xolair; a 3‐year withdrawal follow‐upAllergy, 2009
- Diagnostic Tests Based on Human Basophils: Potentials, Pitfalls and PerspectivesInternational Archives of Allergy and Immunology, 2006
- Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human systemAllergy, 2005
- Application of Human Fc.EPSILON.RI .ALPHA.-Chain-Transfected RBL-2H3 Cells for Estimation of Active Serum IgE.Biological and Pharmaceutical Bulletin, 2003
- Secretory lysosomesNature Reviews Molecular Cell Biology, 2002
- Monomeric IgE Stimulates Signaling Pathways in Mast Cells that Lead to Cytokine Production and Cell SurvivalImmunity, 2001
- Biologic allergen assay for in vivo test allergens with an in vitro model of the murine type I reactionJournal of Allergy and Clinical Immunology, 1997